{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T04:27:20Z","timestamp":1771561640813,"version":"3.50.1"},"reference-count":36,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2018,8,9]],"date-time":"2018-08-09T00:00:00Z","timestamp":1533772800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100002998","name":"College ter Beoordeling van Geneesmiddelen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002998","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>Domperidone is used to treat gastrointestinal symptoms in patients with Parkinson's disease (PD) and is linked to an increased risk of mortality. We sought to examine the risk of all\u2010cause mortality associated with domperidone exposure in PD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a cohort study using data from the Clinical Practice Research Datalink database (1987\u20132011). The first recorded PD diagnosis defined index date. Time\u2010dependent Cox proportional hazards models estimated hazard ratios (HRs) of all\u2010cause mortality associated with domperidone use. PD patients were stratified by domperidone use (current\/recent\/past), with never used as the referent. Current domperidone users were stratified by daily dose, domperidone duration and other anti\u2010Parkinson's medications. A secondary analysis compared PD patients to matched (1:1) non\u2010PD patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 5114 PD patients were identified. Current use of domperidone among PD patients was associated with a two\u2010fold increase in all\u2010cause mortality (HR<jats:sub>adj<\/jats:sub>\u00a0=\u00a02.00, 95% confidence interval [CI]: 1.64\u20132.45), as compared to patients never exposed to domperidone. All\u2010cause mortality risk was highest in those starting domperidone in the previous month [HR<jats:sub>adj<\/jats:sub>\u00a0=\u00a02.97, 95% CI: 2.06\u20134.27]. When compared to matched non\u2010PD patients, PD was associated with a 43% increased risk of all\u2010cause mortality, yet this increased to a 2.4\u2010fold increased risk among PD patients currently using domperidone.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Current use of domperidone was associated with a two\u2010fold increased mortality risk in PD patients, as compared to PD patients that never used domperidone. The risk is highest in the first month of use and does not appear to be attributable to PD alone.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13708","type":"journal-article","created":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T18:14:08Z","timestamp":1530814448000},"page":"2551-2561","source":"Crossref","is-referenced-by-count":16,"title":["Increased risk of all\u2010cause mortality associated with domperidone use in Parkinson's patients: a population\u2010based cohort study in the UK"],"prefix":"10.1111","volume":"84","author":[{"given":"Marina","family":"Simeonova","sequence":"first","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy University of Toronto  Toronto ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"de Vries","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences Utrecht University  Utrecht The Netherlands"},{"name":"Care and Public Health Research Institute (CAPHRI)  Maastricht The Netherlands"},{"name":"Department of Clinical Pharmacy and Toxicology Maastricht University Medical Centre Maastricht  The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sander","family":"Pouwels","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences Utrecht University  Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna H. M.","family":"Driessen","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences Utrecht University  Utrecht The Netherlands"},{"name":"NUTRIM School Maastricht, the Netherlands for Nutrition and Translational Research in Metabolism Maastricht University  The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert G.M.","family":"Leufkens","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences Utrecht University  Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne M.","family":"Cadarette","sequence":"additional","affiliation":[{"name":"Leslie Dan Faculty of Pharmacy University of Toronto  Toronto ON Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-8530","authenticated-orcid":false,"given":"Andrea M.","family":"Burden","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences Utrecht University  Utrecht The Netherlands"},{"name":"Department of Clinical Pharmacy and Toxicology Maastricht University Medical Centre Maastricht  The Netherlands"},{"name":"Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences ETH  Z\u00fcrich Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,8,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000610"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.14802\/jmd.15008"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574886311308010009"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01255.x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.289.6458.1579"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/096032718500400608"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)92959-9"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.16.1883"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02722.x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi312"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.2016"},{"key":"e_1_2_10_13_1","unstructured":"European Medicines Agency Statement.Restrictions on the use of doperidone\u2010containing medicines.2014."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/11536840-000000000-00000"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0000000000000439"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.14802\/jmd.16001"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.09.036"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2001.104002092.x"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12964"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03537.x"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp10X483562"},{"key":"e_1_2_10_23_1","volume-title":"Parkinson's disease: national clinical guideline for diagnosis and management in primary and secondary care","author":"National Collaborating Centre for Chronic Conditions","year":"2006"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2300-2"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13878"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0338-0"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1995.tb00466.x"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1997.00550150024011"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(99)01688-1"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.9.s3.9.x"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2009.03496.x"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000303818.38960.44"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-004-1705-4"},{"key":"e_1_2_10_35_1","volume-title":"Registries for evaluating patient outcomes: a user's guide","author":"Leavy M","year":"2014"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2004.10.012"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.30"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13708","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13708","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.13708","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T12:30:49Z","timestamp":1694349049000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,9]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1111\/bcp.13708"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13708","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,9]]}}}